Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

(Reuters) -OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Lilly makes tirzepatide, commercialized under the name Zepbound for weight loss and Mounjaro for type ... GLP-1 receptor agonist in late-stage trials right now. And just recently Amgen said it's ...

Last week, Eli Lilly, the maker of Zepbound, also cut prices for its starter dose to $349 per month. Larger doses will now cost $499 per month through the company’s self-pay program.

MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% at 52 weeks. Treatment adherence is a major challenge in diabetes, and ...

placebo. Also Read: Amgen Challenges Novo Nordisk’s Ozempic And Eli Lilly’s Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials In addition, IGNITE met the endpoint ...